Table 2 Prevalence of drug resistance mutations.

From: Virological outcomes and treatment retention in North Vietnam amidst transition to social insurance-based HIV services and dolutegravir-based regimens

 

n (%)a

Participants who had HIV-VL ≥ 1000 copies/mL at and after the first visit

75 (3.4)

Participants with HIV-DR testing completed (any region) at least once

69 (3.1)

DRMs (any)

32 (1.4)

DRMs (any NRTIs)

17 (0.8)

DRMs (any NNRTIs)

30 (1.3)

DRMs (any PIs)

3 (0.1)

DRMs (any INSTIs)b

0 (0.0)

DRMs (NRTIs + NNRTIs)

16 (0.7)

DRMs (NRTIs + PIs)

1 (0.0)

DRMs (NRTIs + NNRTIs + PIs)

1 (0.0)

  1. a The percentage was calculated with the total number of participants as the denominator (n = 2,233).
  2. b Drug resistance testing covering the integrase region was performed in patients who had received or were receiving a DTG-containing regimen (n = 39).
  3. HIV-VL, HIV viral load; HIV-DR, HIV drug resistance; DRMs, drug resistance mutations; NRTIs, nucleos(t)ide analogue reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; INSTIs, integrase strand transfer inhibitors.
  4. Sanger sequencing was conducted for the regions of HIV-1 protease (amino acids 1–99), reverse transcriptase (1–560), and integrase (1–289).
Back to article page